Aberrant expression of CHFR in malignant peripheral nerve sheath tumors

Modern Pathology

Volumn 19, Issue 4, 2006, Pages 524-532

  Kobayashi, Chikashi ^a   Oda, Yoshinao ^a   Takahira, Tomonari ^a   Izumi, Teiyu ^a   Kawaguchi, Kenichi ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Yamada, Tomomi ^a   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CHFR; MPNST; Prognosis

Indexed keywords

CHECKPOINT WITH FORKHEAD ASSOCIATED DOMAIN AND RING FINGER PROTEIN; KI 67 ANTIGEN; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LABELING INDEX; MALE; MITOSIS; NERVE SHEATH TUMOR; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NERVE SHEATH NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33645294004     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800548     Document Type: Article

References (36)

1. Plaat BE, Molenaar WM, Mastik MF, et al. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs neurofibromatosis-type-1-associated malignant schwannomas. Int J Cancer 1999;83:171-178.
2. Mertens F, Dal CinP, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol 2000;190:31-38.
3. Kobayashi C, Oda Y, Takahira T, et al. Chromosomal aberration and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from 9 patients. Cancer Genet Cytogenet, in press.
4. Perrone F, Tabano S, Colombo F, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 2003;9:4132-4138.
5. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 2001;81:833-844.
6. Bunz F, Fauth C, Speicher MR, et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002;62:1129-1133.
7. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997;88:315-321.
8. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392:300-303.
9. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 2004;101:8699-8704.
10. Haruki N, Saito H, Harano T, et al. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett 2001;162:201-205.
11. Gemma A, Hosoya Y, Seike M, et al. Genomic structure of the human MAD2 gene and mutation analysis in human lung and breast cancers. Lung Cancer 2001;32:289-295.
12. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000;406:430-435.
13. Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 2002;23:1695-1699.
14. Bertholon J, Wang Q, Falette N, et al. Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene 2003;22:8956-8960.
15. Corn PG, Summers MK, Fogt F, et al. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003;24:47-51.
16. Satoh A, Toyota M, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-8613.
17. Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003;100:7818-7823.
18. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37-42.
19. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
20. Hasegawa T, Yokoyama R, Lee YH, et al. Prognostic relevance of a histological grading system using MIB-1 for adult soft-tissue sarcoma. Oncology 2000;58:66-74.
21. National Institute of Health. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1998;45:575-578.
22. Fleming ID, Cooper JS, Henson DE, et al (eds). American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual, 5th edn. J.B. Lippincott: Philadelphia, 1997.
23. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
24. Parham DM, Webber BL, Jenkins III JJ, et al. Non-rhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol 1995;8:705-710.
25. Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003;27:1337-1345.
26. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors, 4th edn. St Louis: Mosby, 2001.
27. Daniels MJ, Marson A, Venkitaraman AR. PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein. Nat Struct Mol Biol 2004;11:1114-1121.
28. Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-1891.
29. Chaturvedi P, Sudakin V, Bobiak ML, et al. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 2002;62:1797-1801.
30. Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005;37:401-406.
31. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065.
32. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-831.
33. Miyoshi Y, Iwao K, Egawa C, et al. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92:370-373.
34. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002;21:483-492.
35. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-360.
36. Adachi T, Oda Y, Sakamoto A, et al. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int J Surg Pathol 2001;9:99-109.